{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:34:14Z","timestamp":1788453254453,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chimeric antigen receptor T-cell therapy targeting CD19 (CART19) has expanded the treatment options for patients with relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (ALL). The approval of tisagenlecleucel for pediatric and young adult patients with r\/r ALL has allowed broader access for some patients, but the treatment of older adults is available (at the time of this writing) only within a clinical trial. High remission rates have been consistently observed with varied CART19 products and treatment platforms, but durability of remissions and thus the potential role of a consolidative allogeneic stem cell transplant (SCT) is more uncertain and likely to vary by product and population treated. The immunologic characteristics of CARTs that confer high response rates also account for the life-threatening toxicities of cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome, the severity of which also varies by patient and disease characteristics and product. Further considerations informing a decision to treat include feasibility of leukapheresis and timeline of manufacture, alternative treatment options available, and the appropriateness of a potential consolidative allogeneic SCT. Advances in the field are under way to improve rate and duration of responses and to mitigate toxicity.<\/jats:p>","DOI":"10.1182\/hematology.2021000225","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:06:49Z","timestamp":1639138009000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Relapsed ALL: CAR T vs transplant vs novel therapies"],"prefix":"10.1182","volume":"2021","author":[{"given":"Noelle V.","family":"Frey","sequence":"first","affiliation":[{"name":"Cell Therapy and Transplant Program, Abramson Cancer Center, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"5","key":"2021121012063527600_hem2021000225C1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"2021121012063527600_hem2021000225C2","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2021121012063527600_hem2021000225C3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2021121012063527600_hem2021000225C4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open- label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"issue":"16","key":"2021121012063527600_hem2021000225C5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121012063527600_hem2021000225C6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"27","key":"2021121012063527600_hem2021000225C7","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021121012063527600_hem2021000225C8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed\/refractory malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"issue":"5","key":"2021121012063527600_hem2021000225C9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2021121012063527600_hem2021000225C10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16623","article-title":"Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia","volume":"191","author":"Wang","year":"2020","journal-title":"Br J Haematol"},{"issue":"15","key":"2021121012063527600_hem2021000225C11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10299","key":"2021121012063527600_hem2021000225C12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2021121012063527600_hem2021000225C13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2021121012063527600_hem2021000225C14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021121012063527600_hem2021000225C15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"2021121012063527600_hem2021000225C16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"22","key":"2021121012063527600_hem2021000225C17","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"24","key":"2021121012063527600_hem2021000225C18","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021121012063527600_hem2021000225C19","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"2021121012063527600_hem2021000225C20","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"2021121012063527600_hem2021000225C21","doi-asserted-by":"crossref","unstructured":"Jacoby\n              E\n            , NguyenSM, FountaineTJ, et al.\n          CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320. doi:10.1038\/ncomms12320.","DOI":"10.1038\/ncomms12320"},{"key":"2021121012063527600_hem2021000225C22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre- existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"2021121012063527600_hem2021000225C23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"},{"key":"2021121012063527600_hem2021000225C24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"2021121012063527600_hem2021000225C25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2021121012063527600_hem2021000225C26","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2021121012063527600_hem2021000225C27","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/ajh.25442","article-title":"Chimeric antigen receptor T cells for acute lymphoblastic leukemia","volume":"94","author":"Frey","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2021121012063527600_hem2021000225C28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2021121012063527600_hem2021000225C29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"2021121012063527600_hem2021000225C30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2021121012063527600_hem2021000225C31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"2021121012063527600_hem2021000225C32","doi-asserted-by":"crossref","first-page":"605766","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"2021121012063527600_hem2021000225C33","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"2021121012063527600_hem2021000225C34","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/1\/1851774\/1frey.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/1\/1851774\/1frey.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:07:15Z","timestamp":1639138035000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/1\/482961\/Relapsed-ALL-CAR-T-vs-transplant-vs-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000225","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}